Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zishen Yutai Pill for Patients With Recurrent Implantation Failure
NCT07641088Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Randomised, double-blind trial in Recurrent Implantation Failure (RIF) comparing ZYP group with Placebo group (2 arms). Primary endpoint: Live birth rate at 52 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Zishen Yutai Pill
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT07641088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07641088.